Tilray Medical, a subsidiary of a leading global cannabis and consumer packaged goods company, has received approval for a new medical cannabis extract in Portugal. The extract, known as Tilray Oral Solution THC10:CBD10, has been approved for medical use in the country. This approval aligns with Tilray’s commitment to providing high-quality cannabis products for patients with specific medical conditions.
Denise Faltischek, Tilray’s head of international and chief strategy officer, emphasized the significance of this approval in meeting the critical needs of patient care. This approval marks the introduction of the third medical cannabis product by Tilray Medical in Portugal. Earlier this year, Tilray Medical received approval for the first cannabis extract and whole flower THC 18 in the country.
Tilray’s global presence includes operations in over 20 countries, with a portfolio of more than 20 brands. The company has been a pioneer in the production of medical cannabis, with GMP-certified facilities in Europe. Tilray stock last traded at C$2.60 per share, demonstrating both year-over-year growth and long-term performance.
For additional insight and discussion on Tilray and related topics, individuals can engage with the Tilray Brands Inc. Bullboard and explore Stockhouse’s stock forums and message boards. It’s important to note that the information provided in this article is for informational purposes only and should not be considered as investment advice. Please refer to the full disclaimer information for complete details.
